Actinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual Meeting

- Company’s Actimab-A and Actimab-M programs to be presented at the conference

NEW YORK, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc (NYSE American:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company will feature two posters highlighting its Actimab-A Phase 2 and Actimab-M Phase 1 clinical trials at the Society of Hematologic Oncology 2017 Annual Meeting (SOHO). The posters will be presented as part of the Clinical Trials in Progress section.

“SOHO is an excellent opportunity to share the potential of our CD33 targeting alpha-particle therapy candidates with the greater hematology community,” said Dr. Mark Berger, Actinium’s Chief Medical Officer. “We are excited to demonstrate the capacity of our Alpha Therapy platform to bring trials to the clinic addressing unmet clinical needs.”

Actimab-A is enrolling patients in a multicenter Phase 2 trial for patients newly diagnosed with Acute Myeloid Leukemia who are age 60 and above and unfit for standard induction therapy. Actimab-M is a Phase 1 trial that is enrolling patients diagnosed with refractory Multiple Myeloma.

SOHO is expected to draw physicians, researchers, and industry leaders from across the nation and will be held at the Westin Galleria & Oaks in Houston, Texas from September 13th – 16th.

The details of the poster presentations are as follows:

Title: Trial in Progress: A Phase I/II Study of Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia
Abstract Number: AML-070

Title: Trial in Progress: Phase I Study of Actinium-225 (225Ac)-Lintuzumab in Patients with Refractory Multiple Myeloma
Abstract Number: MM-77

Date: Wednesday, September 13th, 2017
Time: 6:00 – 9:00 PM
Location: Westin Galleria

About Actimab-A

Actimab-A, Actinium's most advanced alpha-particle candidate, is currently in a 53-patient, multicenter Phase 2 trial for patients newly diagnosed with AML age 60 and above. Actimab-A is being developed as a first-line therapy and is a monotherapy that is administered via two 15-minute injections that are given 7 days apart. Actimab-A targets CD33, a protein abundantly expressed on the surface of AML cells via the monoclonal antibody, HuM195, which carries the potent cytotoxic radioisotope actinium-225 to the AML cancer calls. Actinium-225 gives off high- energy alpha particles as it decays, which kill cancer cells and as actinium-225 decays it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. Actimab-A is a second-generation therapy from the Company’s HuM195-Alpha program, which was developed at Memorial Sloan Kettering Cancer Center and has now been studied in almost 90 patients in four clinical trials. Actimab-A has been granted Orphan Drug Designation for newly diagnosed AML age 60 and above.

About Actimab-M

The Actimab-M trial uses a CD33 targeted therapy coupled to actinium 225 (the same agent used in the Actimab-A program), and is in a Phase 1 open label, dose escalation study for patients who have progressing disease after 3 prior multiple myeloma treatment regimens. The Phase 1 trial will estimate maximum tolerated dose (MTD), assess adverse events, measure response rates (objective response rate, complete response rate, stringent complete response rate, very good partial response rate and partial response rate) as well as progression free survival (PFS) and overall survival (OS).

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. Actinium is also utilizing its alpha-particle technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more about Actinium Pharmaceuticals, please visit and to follow @ActiniumPharma on Twitter please visit,

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.  

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Principal Financial Officer

Liolios Investor Relations
Marek Ciszewski, J.D.